Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer
Authors:
- James SpicerJSJames Spicer
- Mrcp MbbsMMMrcp Mbbs
- 1 March 2009
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 18 (3) , 293-301
Abstract
Inhibiting the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) has an established role in the treatment of advanced non-small cell lung cancer. The first-generation EGFR inhibitors erlotinib and gefitinib have been approved for treatment in the second- and third-line setting. Second-generation EGFR tyrosine kinase inhibitors are now in development aiming to improve efficacy and overcome primary and secondary resistance to the first-generation drugs. The two most common strategies being used to achieve these aims are irreversible binding of drug to target and kinase multi-targeting. This is an overview of the early clinical development of selected second-generation tyrosine kinase inhibitors focusing on the treatment of non-small cell lung cancer.Keywords
This publication has 46 references indexed in Scilit:
- Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopesCurrent Opinion in Oncology, 2008
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Association of HER‐2 overexpression with prognosis in nonsmall cell lung carcinoma: A metaanalysisCancer, 2005
- Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung CancersJNCI: Journal of the National Cancer Institute, 2005
- Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung CancerJAMA, 2003
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Untangling the ErbB signalling networkNature Reviews Molecular Cell Biology, 2001
- The ErbB signaling network: receptor heterodimerization in development and cancerThe EMBO Journal, 2000
- Epidermal growth factor receptors in lung tumoursThe Journal of Pathology, 1987